共 50 条
- [1] The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors[J]. CLINICAL CHEMISTRY, 2019, 65 (02) : 357 - 357Nandakumar, VijayalakshmiMills, John R.
- [2] Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence[J]. ONCOLOGIST, 2020, 25 (01): : E147 - E159Klempner, Samuel J.Fabrizio, DavidBane, ShalmaliReinhart, MarciaPeoples, TimAli, Siraj M.Sokol, Ethan S.Frampton, GarrettSchrock, Alexa B.Anhorn, RachelReddy, Prasanth
- [3] Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math[J]. Strahlentherapie und Onkologie, 2018, 194 : 873 - 875Frank A. GiordanoMarlon R. VeldwijkCarsten HerskindFrederik Wenz
- [4] Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 (10) : 873 - 875Giordano, Frank A.Veldwijk, Marlon R.Herskind, CarstenWenz, Frederik
- [5] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors[J]. NATURE COMMUNICATIONS, 2021, 12 (01)Valero, CristinaLee, MarkHoen, DouglasWeiss, KateKelly, Daniel W.Adusumilli, Prasad S.Paik, Paul K.Plitas, GeorgeLadanyi, MarcPostow, Michael A.Ariyan, Charlotte E.Shoushtari, Alexander N.Balachandran, Vinod P.Hakimi, A. AriCrago, Aimee M.Roche, Kara C. LongSmith, J. JoshuaGanly, IanWong, Richard J.Patel, Snehal G.Shah, Jatin P.Lee, Nancy Y.Riaz, NadeemWang, JingmingZehir, AhmetBerger, Michael F.Chan, Timothy A.Seshan, Venkatraman E.Morris, Luc G. T.
- [6] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors[J]. Nature Communications, 12Cristina ValeroMark LeeDouglas HoenKate WeissDaniel W. KellyPrasad S. AdusumilliPaul K. PaikGeorge PlitasMarc LadanyiMichael A. PostowCharlotte E. AriyanAlexander N. ShoushtariVinod P. BalachandranA. Ari HakimiAimee M. CragoKara C. Long RocheJ. Joshua SmithIan GanlyRichard J. WongSnehal G. PatelJatin P. ShahNancy Y. LeeNadeem RiazJingming WangAhmet ZehirMichael F. BergerTimothy A. ChanVenkatraman E. SeshanLuc G. T. Morris
- [7] Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors[J]. BRAIN TUMOR PATHOLOGY, 2023, 40 (03) : 185 - 190Shinojima, NaokiOzono, KazutakaYamamoto, HaruakiAbe, SakikoSasaki, RumiTomita, YusukeKai, AzusaMori, RyosukeYamamoto, TakahiroUekawa, KenMatsui, HirotakaNosaka, KisatoMatsuzaki, HiroakiKomohara, YoshihiroMikami, YoshikiMukasa, Akitake
- [8] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors[J]. CANCER CELL, 2022, 40 (10) : 1161 - +Nassar, Amin H.Adib, ElioAlaiwi, Sarah AbouEl Zarif, TalalGroha, StefanAkl, Elie W.Nuzzo, Pier VitaleMouhieddine, Tarek H.Perea-Chamblee, TominTaraszka, KodiEl-Khoury, HabibLabban, MuhieddineFong, ChristopherArora, Kanika S.Labaki, ChrisXu, WenxinSonpavde, GuruHaddad, Robert I.Mouw, Kent W.Giannakis, MariosHodi, F. StephenZaitlen, NoahSchoenfeld, Adam J.Schultz, NikolausBerger, Michael F.MacConaill, Laura E.Ananda, GuruprasadKwiatkowski, David J.Choueiri, Toni K.Schrag, DeborahCarrot-Zhang, JianGusev, Alexander
- [9] Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors[J]. Brain Tumor Pathology, 2023, 40 : 185 - 190Naoki ShinojimaKazutaka OzonoHaruaki YamamotoSakiko AbeRumi SasakiYusuke TomitaAzusa KaiRyosuke MoriTakahiro YamamotoKen UekawaHirotaka MatsuiKisato NosakaHiroaki MatsuzakiYoshihiro KomoharaYoshiki MikamiAkitake Mukasa
- [10] Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer[J]. ANNALS OF ONCOLOGY, 2019, 30 (07) : 1096 - 1103Schrock, A. B.Ouyang, C.Sandhu, J.Sokol, E.Jin, D.Ross, J. S.Miller, A.Lim, D.Amanam, IChao, J.Catenacci, D.Cho, M.Braiteh, F.Klempner, S. J.Ali, S. M.Fakih, M.